D&D Pharmatech (347850.KQ)
KRW 47200.0
(0.21%)
KRW 47200.0
(0.21%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -7.5 Billion KRW | -534.16% |
| 2022 | 1.72 Billion KRW | 105.34% |
| 2021 | -32.38 Billion KRW | 41.0% |
| 2020 | -54.88 Billion KRW | 50.61% |
| 2019 | -111.12 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - KRW | 100.0% |
| 2024 Q2 | -35.28 Billion KRW | 0.0% |
| 2023 Q1 | - KRW | -100.0% |
| 2023 FY | -7.5 Billion KRW | -534.16% |
| 2023 Q4 | -7.5 Billion KRW | 24.24% |
| 2023 Q3 | -9.9 Billion KRW | 0.0% |
| 2022 Q4 | 1.72 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 83.743% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 81.501% |
| BINEX Co., Ltd. | 45.34 Billion KRW | 116.556% |
| Bioneer Corporation | -3.9 Billion KRW | -92.124% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | 189.895% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | 150.679% |
| CrystalGenomics, Inc. | 8.99 Billion USD | 183.495% |
| Helixmith Co., Ltd | -24.42 Billion KRW | 69.263% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 101.93% |
| Medy-Tox Inc. | 49.58 Billion KRW | 115.142% |
| Peptron, Inc. | 4.86 Billion KRW | 254.208% |
| Amicogen, Inc. | 125.26 Billion KRW | 105.994% |
| Genexine, Inc. | 61.39 Billion KRW | 112.229% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | 45.146% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 86.606% |
| ALTEOGEN Inc. | 53.56 Billion KRW | 114.015% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 77.207% |
| SillaJen, Inc. | -13.89 Billion KRW | 45.954% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 108.908% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | 127.426% |
| Genomictree Inc. | -43.43 Billion KRW | 82.715% |
| MedPacto, Inc. | -64 Billion KRW | 88.269% |
| EASY BIO,Inc. | 53.21 Billion KRW | 114.11% |
| GI Innovation, Inc. | -4.82 Billion KRW | -55.683% |